Your browser doesn't support javascript.
loading
Antimicrobial and anti-inflammatory activities of chemokine CXCL14-derived antimicrobial peptide and its analogs.
Rajasekaran, Ganesan; Dinesh Kumar, S; Nam, Jiyoung; Jeon, Dasom; Kim, Yangmee; Lee, Chul Won; Park, Il-Seon; Shin, Song Yub.
Afiliação
  • Rajasekaran G; Department of Cellular and Molecular Medicine, Chosun University, Gwangju 61452, Republic of Korea.
  • Dinesh Kumar S; Department of Cellular and Molecular Medicine, Chosun University, Gwangju 61452, Republic of Korea.
  • Nam J; Department of Chemistry, Chonnam National University, Gwangju 61186, Republic of Korea.
  • Jeon D; Department of Bioscience and Biotechnology, Konkuk University, Seoul 05029, Republic of Korea.
  • Kim Y; Department of Bioscience and Biotechnology, Konkuk University, Seoul 05029, Republic of Korea.
  • Lee CW; Department of Chemistry, Chonnam National University, Gwangju 61186, Republic of Korea.
  • Park IS; Department of Cellular and Molecular Medicine, Chosun University, Gwangju 61452, Republic of Korea.
  • Shin SY; Department of Cellular and Molecular Medicine, Chosun University, Gwangju 61452, Republic of Korea. Electronic address: syshin@chosun.ac.kr.
Biochim Biophys Acta Biomembr ; 1861(1): 256-267, 2019 01.
Article em En | MEDLINE | ID: mdl-29959905
CXCL14 is a CXC chemokine family that exhibits antimicrobial activity and contains an amphipathic cationic α-helical region in the C-terminus, a characteristic structure of antimicrobial peptides (AMPs). In this study, we designed three analogs of CXCL1459-75 (named CXCL14-C17) corresponding to the C-terminal α-helix of CXCL14, which displayed potential antimicrobial activity against a wide variety of gram-negative and gram-positive bacteria with minimum inhibitory concentrations of 4-16 µM without mammalian cell toxicity. Furthermore, two CXCL14-C17 analogs (CXCL14-C17-a1 and CXCL14-C17-a3) with improved cell selectivity were engineered by introducing Lys, Arg, or Trp in CXCL14-C17. Additionally, CXCL14-C17 analogs showed much greater synergistic effect (FICI: 0.3125-0.375) with chloramphenicol and ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa (MDRPA) than LL-37 did (FICI: 0.75-1.125). CXCL14-C17 analogs were more active against antibiotic-resistant bacteria including methicillin-resistant Staphylococcus aureus (MRSA), MDRPA, and vancomycin-resistant Enterococcus faecium (VREF) than LL-37 and melittin. In particular, CXCL14-C17-a2 and CXCL14-C17-a3 completely inhibited the biofilm formation at sub-MIC and all of the peptides were able to eliminate pre-formed biofilm as well. Membrane depolarization, flow cytometry, sytox green uptake, ONPG hydrolysis and confocal microscopy revealed the possible target of the native peptide (CXCL14-C17) to likely be intracellular, and the amphipathic designed analogs targeted the bacterial membrane. CXCL14-C17 also showed DNA binding characteristic activity similar to buforin-2. Interestingly, CXCL14-C17-a2 and CXCL14-C17-a3 effectively inhibited the production and expression of nitric oxide (NO), tumor necrosis factor (TNF)-α, interleukin (IL)-6, and monocyte chemoattractant protein (MCP)-1 from lipopolysaccharide (LPS)-stimulated RAW264.7 cells, suggesting that these peptides could be promising anti-inflammatory and antimicrobial agents.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quimiocinas CXC / Peptídeos Catiônicos Antimicrobianos / Anti-Infecciosos / Anti-Inflamatórios Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quimiocinas CXC / Peptídeos Catiônicos Antimicrobianos / Anti-Infecciosos / Anti-Inflamatórios Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article